{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:10:18Z","timestamp":1787987418931,"version":"build-2784847793"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12215-w","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:20:43Z","timestamp":1782858043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging molecular targets in gynaecologic cancers: clinical implications for personalized therapy"],"prefix":"10.1007","volume":"53","author":[{"given":"Babulla","family":"Shaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounika","family":"Thokala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firdosh","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravani","family":"Nakka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman Basha","family":"Pinjari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben Babu","family":"Marabathula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"AL-Farga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muni Kumari","family":"Anday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"12215_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.canlet.2020.12.042","volume":"502","author":"V Bhardwaj","year":"2021","unstructured":"Bhardwaj V, Tan YQ, Wu MM, Ma L, Zhu T, Lobie PE, Pandey V (2021) Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives. Cancer Lett 502:97\u2013107","journal-title":"Cancer Lett"},{"issue":"14","key":"12215_CR2","doi-asserted-by":"publisher","first-page":"7996","DOI":"10.3390\/ijms25147996","volume":"25","author":"T Wolde","year":"2024","unstructured":"Wolde T, Bhardwaj V, Reyad-ul-Ferdous M, Qin P, Pandey V (2024) The integrated bioinformatic approach reveals the prognostic significance of LRP1 expression in ovarian cancer. Int J Mol Sci 25(14):7996","journal-title":"Int J Mol Sci"},{"key":"12215_CR3","doi-asserted-by":"publisher","unstructured":"Zhu B, Gu H, Mao Z, Beeraka NM, Zhao X, Anand MP, Zheng Y, Zhao R, Li S, Manogaran P, Fan R, Nikolenko VN, Wen H, Basappa B, Liu J (2024) Global burden of gynaecological cancers in 2022 and projections to 2050. Journal of Global Health, 14. https:\/\/doi.org\/10.7189\/jogh.14.04155","DOI":"10.7189\/jogh.14.04155"},{"issue":"8","key":"12215_CR4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00432-025-06277-9","volume":"151","author":"Y Ren","year":"2025","unstructured":"Ren Y, Xu R, Wang Y, Su L, Su J (2025) Global, regional, and national burden of ovarian cancer in women aged 45\u2009+\u2009from 1990 to 2021 and projections for 2050. J Cancer Res Clin Oncol 151(8):225. https:\/\/doi.org\/10.1007\/s00432-025-06277-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"12215_CR5","doi-asserted-by":"publisher","unstructured":"Mao Y, Gao Y, He Y, Wan Z, Li S, Ding Z, Hu B, Fu L, Luo C, Zhu S, Cao W (2025) Global burden of cancer in women, 1990\u20132021: A systematic analysis from the GBD 2021 study. Front Oncol 15. https:\/\/doi.org\/10.3389\/fonc.2025.1633894","DOI":"10.3389\/fonc.2025.1633894"},{"key":"12215_CR6","doi-asserted-by":"publisher","unstructured":"Mazidimoradi A, Momenimovahed Z, Khani Y, Rezaei Shahrabi A, Allahqoli L, Salehiniya H (2023) Global patterns and temporal trends in ovarian cancer morbidity, mortality, and burden from 1990 to 2019. https:\/\/doi.org\/10.1515\/oncologie-2023-0172. Oncologie","DOI":"10.1515\/oncologie-2023-0172"},{"key":"12215_CR7","doi-asserted-by":"publisher","unstructured":"Somasegar S, Montes de MK, Karam A, Rossi E, Obermair A (2024) Controversies in the surgical management of gynaecologic cancer. ASCO Educational Book 44(3). https:\/\/doi.org\/10.1200\/edbk_438550","DOI":"10.1200\/edbk_438550"},{"issue":"1","key":"12215_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2217\/17455057.2.1.127","volume":"2","author":"GH Eltabbakh","year":"2006","unstructured":"Eltabbakh GH, Goodrich S (2006) Update on the treatment of recurrent ovarian cancer. Women\u2019s Health 2(1):127\u2013139. https:\/\/doi.org\/10.2217\/17455057.2.1.127","journal-title":"Women\u2019s Health"},{"key":"12215_CR9","doi-asserted-by":"publisher","DOI":"10.31832\/smj.1309164","author":"H Halis","year":"2023","unstructured":"Halis H, A\u00e7\u0131kg\u00f6z SG (2023) Survival, failure patterns, and toxicity outcomes in endometrial cancer patients receiving adjuvant radiotherapy. Sakarya T\u0131p Dergisi. https:\/\/doi.org\/10.31832\/smj.1309164","journal-title":"Sakarya T\u0131p Dergisi"},{"issue":"11","key":"12215_CR10","doi-asserted-by":"publisher","first-page":"102119","DOI":"10.1016\/j.ijgc.2025.102119","volume":"35","author":"AE Rosenthal","year":"2025","unstructured":"Rosenthal AE, Posever N, Modest A, Wiechert AC, Jang JW, Esselen KM (2025) Comparative analysis of adjuvant treatment outcomes in stage III endometrial cancer. Int J Gynaecol Cancer 35(11):102119. https:\/\/doi.org\/10.1016\/j.ijgc.2025.102119","journal-title":"Int J Gynaecol Cancer"},{"key":"12215_CR11","doi-asserted-by":"publisher","unstructured":"Aravantinou-Fatorou A, Georgakopoulou V, Dimopoulos MA, Liontos M (2025) Precision medicine in gynaecological cancer (Review). Biomedical Rep 22(3). https:\/\/doi.org\/10.3892\/br.2025.1921","DOI":"10.3892\/br.2025.1921"},{"issue":"1","key":"12215_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.yao.2022.02.001","volume":"2","author":"ME Foxall","year":"2022","unstructured":"Foxall ME, Arend RC (2022) The landscape of personalized medicine in gynaecologic cancer. Adv Oncol 2(1):99\u2013105. https:\/\/doi.org\/10.1016\/j.yao.2022.02.001","journal-title":"Adv Oncol"},{"key":"12215_CR13","doi-asserted-by":"publisher","first-page":"904032","DOI":"10.3389\/fonc.2022.904032","volume":"12","author":"Z Lu","year":"2022","unstructured":"Lu Z, Liu H (2022) Editorial: Molecular targets and therapeutic strategies in gynaecological cancers. Front Oncol 12:904032. https:\/\/doi.org\/10.3389\/fonc.2022.904032","journal-title":"Front Oncol"},{"issue":"4","key":"12215_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/cells13040345","volume":"13","author":"M Murawski","year":"2024","unstructured":"Murawski M, Jagodzi\u0144ski A, Bielawska-Pohl A, Klimczak A (2024) Complexity of the genetic background of oncogenesis in ovarian cancer. Cells 13(4):345","journal-title":"Cells"},{"key":"12215_CR15","doi-asserted-by":"crossref","unstructured":"Bleotu C, Socolov D, Anton M, Botezatu A, Plesa A, Iancu IV, Diaconu CC (2016) Interplay of Epigenetics with Gynaecological Cancer. Gynaecologic Cancers\u2014Basic Sciences, Clinical and Therapeutic Perspectives Bookman MA","DOI":"10.5772\/61032"},{"issue":"13 Suppl","key":"12215_CR16","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1158\/1538-7445.am2018-3303","volume":"78","author":"A Berger","year":"2018","unstructured":"Berger A, Korkut A, Kanchi RS, Mills GB, Levine DA, Akbani R (2018) A comprehensive TCGA pan-cancer molecular study of gynaecologic and breast cancers. Cancer Res 78(13 Suppl):3303. https:\/\/doi.org\/10.1158\/1538-7445.am2018-3303","journal-title":"Cancer Res"},{"issue":"8","key":"12215_CR17","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3390\/cancers11081083","volume":"11","author":"CM Roberts","year":"2019","unstructured":"Roberts CM, Cardenas C, Tedja R (2019) The role of intratumoral heterogeneity and its clinical relevance in epithelial ovarian cancer recurrence and metastasis. Cancers 11(8):1083","journal-title":"Cancers"},{"issue":"2","key":"12215_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Reviews Clin Oncol 15(2):81\u201394. https:\/\/doi.org\/10.1038\/nrclinonc.2017.166","journal-title":"Nat Reviews Clin Oncol"},{"issue":"9","key":"12215_CR19","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.trecan.2023.06.004","volume":"9","author":"MA Goyette","year":"2023","unstructured":"Goyette MA, Lipsyc-Sharf M, Polyak K (2023) Clinical and translational relevance of intratumor heterogeneity. Trends Cancer 9(9):726\u2013737. https:\/\/doi.org\/10.1016\/j.trecan.2023.06.004","journal-title":"Trends Cancer"},{"key":"12215_CR20","doi-asserted-by":"publisher","unstructured":"Pejovic T, Odunsi K (2021) Molecular biology of gynaecological cancers. In F. Okonofua, J. A. Balogun, K. Odunsi, & V. N. Chilaka (Eds.), Contemporary obstetrics and gynecology for developing countries. Springer. https:\/\/doi.org\/10.1007\/978-3-030-75385-6_53","DOI":"10.1007\/978-3-030-75385-6_53"},{"key":"12215_CR21","doi-asserted-by":"publisher","first-page":"584793","DOI":"10.3389\/fonc.2020.584793","volume":"10","author":"Y Guo","year":"2020","unstructured":"Guo Y, Liu J, Luo J, You X, Weng H, Wang M, Ouyang T, Li X, Liao X, Wang M, Lan Z, Shi Y, Chen S (2020) Molecular profiling reveals common and specific development processes in different types of gynaecologic cancers. Front Oncol 10:584793. https:\/\/doi.org\/10.3389\/fonc.2020.584793","journal-title":"Front Oncol"},{"issue":"Suppl 1","key":"12215_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s13193-020-01271-8","volume":"12","author":"TS Shylasree","year":"2021","unstructured":"Shylasree TS, Richa B, Lavanya G, Gulia S (2021) Molecular signatures of gynaecological cancers: Clinicians\u2019 perspective. Indian J Surg Oncol 12(Suppl 1):103\u2013110. https:\/\/doi.org\/10.1007\/s13193-020-01271-8","journal-title":"Indian J Surg Oncol"},{"key":"12215_CR23","doi-asserted-by":"publisher","first-page":"1547083","DOI":"10.3389\/fonc.2025.1547083","volume":"15","author":"J Chen","year":"2025","unstructured":"Chen J, Yin R (2025) AKT inhibitors in gynaecologic oncology: Past, present and future. Front Oncol 15:1547083. https:\/\/doi.org\/10.3389\/fonc.2025.1547083","journal-title":"Front Oncol"},{"issue":"8","key":"12215_CR24","doi-asserted-by":"publisher","first-page":"e70295","DOI":"10.1002\/mco2.70295","volume":"6","author":"M Jiang","year":"2025","unstructured":"Jiang M, Zhang K, Zhang Z, Zeng X, Huang Z, Qin P, Xie Z, Cai X, Ashrafizadeh M, Tian Y, Wei R (2025) PI3K\/AKT\/mTOR axis in cancer: From pathogenesis to treatment. MedComm 6(8):e70295. https:\/\/doi.org\/10.1002\/mco2.70295","journal-title":"MedComm"},{"issue":"21","key":"12215_CR25","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","volume":"18","author":"BM Slomovitz","year":"2012","unstructured":"Slomovitz BM, Coleman RL (2012) The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 18(21):5856\u20135864. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0662","journal-title":"Clin Cancer Res"},{"key":"12215_CR26","doi-asserted-by":"publisher","first-page":"101519","DOI":"10.1016\/j.gendis.2025.101519","volume":"12","author":"C Liu","year":"2025","unstructured":"Liu C, Shi L, Meng Z, Zhang M, Zhang Z, Li Y, Du K, Yang M, Qiu L, Feng J, He Y, Liu J, Zhang H, Lang T, Yang Z (2025) Restriction of YWHAB-mediated YAP cytoplasmic retention is a novel mechanism underlying stemness maintenance and chemoresistance in ovarian cancer peritoneal metastasis. Genes Dis 12:101519. https:\/\/doi.org\/10.1016\/j.gendis.2025.101519","journal-title":"Genes Dis"},{"issue":"1","key":"12215_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s43856-022-00142-3","volume":"2","author":"X Zhang","year":"2022","unstructured":"Zhang X, Wang L, Chen S, Huang P, Ma L, Ding H, Pandey V (2022) Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma. Commun Med 2(1):82","journal-title":"Commun Med"},{"issue":"6","key":"12215_CR28","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1021\/acsptsci.0c00064","volume":"3","author":"Y Wang","year":"2020","unstructured":"Wang Y, Chiou YS, Chong QY, Zhang M, Rangappa KS, Ma L, Lobie PE (2020) Pharmacological inhibition of BAD Ser99 phosphorylation enhances the efficacy of cisplatin in ovarian cancer by inhibition of cancer stem cell-like behavior. ACS Pharmacol Translational Sci 3(6):1083\u20131099","journal-title":"ACS Pharmacol Translational Sci"},{"issue":"1","key":"12215_CR29","doi-asserted-by":"publisher","first-page":"djt350","DOI":"10.1093\/jnci\/djt350","volume":"106","author":"MA Bookman","year":"2014","unstructured":"Bookman MA (2014) Molecular wanderings through the DNA damage response and risk for ovarian cancer. J Natl Cancer Inst 106(1):djt350. https:\/\/doi.org\/10.1093\/jnci\/djt350","journal-title":"J Natl Cancer Inst"},{"key":"12215_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-esgo.398","author":"SD Mittelstadt","year":"2024","unstructured":"Mittelstadt SD, Staebler A, Walter C, Denkert C, Knoll K, Zeimet A, Kommoss S, Grube M (2024) Homologous recombination deficiency (HRD) in primary advanced-stage and recurrent p53-abnormal endometrial carcinoma. Int J Gynaecol Cancer. https:\/\/doi.org\/10.1136\/ijgc-2024-esgo.398","journal-title":"Int J Gynaecol Cancer"},{"key":"12215_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-igcs.11","author":"D Nasioudis","year":"2022","unstructured":"Nasioudis D, Latif NA, Ko EM, Cory L, Haggerty A, Kim S, Morgan MA, Simpkins F, Giuntoli RL, II (2022) Next-generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma. Int J Gynaecol Cancer. https:\/\/doi.org\/10.1136\/ijgc-2022-igcs.11","journal-title":"Int J Gynaecol Cancer"},{"issue":"3","key":"12215_CR32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.critrevonc.2012.04.002","volume":"84","author":"A Bamias","year":"2012","unstructured":"Bamias A, Pignata S, Pujade-Lauraine E (2012) Angiogenesis: A promising therapeutic target for ovarian cancer. Crit Rev Oncol\/Hematol 84(3):314\u2013326. https:\/\/doi.org\/10.1016\/j.critrevonc.2012.04.002","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"12215_CR33","doi-asserted-by":"publisher","first-page":"175586","DOI":"10.1016\/j.ejphar.2023.175586","volume":"949","author":"S Ghalehbandi","year":"2023","unstructured":"Ghalehbandi S, Yuzugulen J, Pranjol MZI, Pourgholami MH (2023) The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol 949:175586. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175586","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"12215_CR34","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.3390\/cancers14051122","volume":"14","author":"L Kasherman","year":"2022","unstructured":"Kasherman L, Liu SL, Karakasis K, Lheureux S (2022) Angiogenesis: A pivotal therapeutic target in the drug development of gynaecologic cancers. Cancers 14(5):1122. https:\/\/doi.org\/10.3390\/cancers14051122","journal-title":"Cancers"},{"key":"12215_CR35","doi-asserted-by":"crossref","unstructured":"Bhardwaj V, Zhang X, Pandey V, Garg M (2023) Neo-vascularization-based therapeutic perspectives in advanced ovarian cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 1878(3):188888","DOI":"10.1016\/j.bbcan.2023.188888"},{"issue":"2\u20133","key":"12215_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12672-019-0358-9","volume":"10","author":"AC Rodriguez","year":"2019","unstructured":"Rodriguez AC, Blanchard Z, Maurer KA, Gertz J (2019) Estrogen signaling in endometrial cancer: A key oncogenic pathway with several open questions. Horm Cancer 10(2\u20133):51\u201363. https:\/\/doi.org\/10.1007\/s12672-019-0358-9","journal-title":"Horm Cancer"},{"issue":"1","key":"12215_CR37","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1038\/s41467-022-30898-0","volume":"13","author":"V Scabia","year":"2022","unstructured":"Scabia V, Ayyanan A, De Martino F, Agnoletto A, Battista L, Laszlo C, Treboux A, Zaman K, Stravodimou A, Jallut D, Fiche M, Bucher P, Ambrosini G, Sflomos G, Brisken C (2022) Estrogen receptor\u2013positive breast cancers rely on progesterone receptor. Nat Commun 13(1):3127","journal-title":"Nat Commun"},{"key":"12215_CR38","doi-asserted-by":"crossref","unstructured":"Pandey, V., Perry, J. K., Mohankumar, K. M., Kong, X. J., Liu, S. M., Wu, Z. S.,\u2026 Lobie, P. E. (2008). Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology, 149(8), 3909\u20133919","DOI":"10.1210\/en.2008-0286"},{"key":"12215_CR39","doi-asserted-by":"crossref","unstructured":"Zhang X, Pandey V, Bhardwaj V, Zhu T, Lobie PE (2024) Autocrine\/paracrine growth hormone in cancer progression. Endocrine-related Cancer, 31(1)","DOI":"10.1530\/ERC-23-0120"},{"issue":"15","key":"12215_CR40","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.3390\/cancers15153849","volume":"15","author":"D Margul","year":"2023","unstructured":"Margul D, Yu C, AlHilli MM (2023) Tumor immune microenvironment in gynaecologic cancers. Cancers 15(15):3849. https:\/\/doi.org\/10.3390\/cancers15153849","journal-title":"Cancers"},{"key":"12215_CR41","doi-asserted-by":"publisher","unstructured":"Kitapl\u0131 S, Alkan A (2024) Immunotherapy in Gynaecologic (Ovary, Endometrium and Servics) Cancer. 219\u2013228. https:\/\/doi.org\/10.69860\/nobel.9786053359388.15","DOI":"10.69860\/nobel.9786053359388.15"},{"key":"12215_CR42","doi-asserted-by":"publisher","unstructured":"Zhang Z, Liu M, An Y, Gao C, Wang T, Zhang G, Li S, Li W, Li M, Wang G (2025) Targeting immune microenvironment in cervical cancer. J Translational Med 23(1). https:\/\/doi.org\/10.1186\/s12967-025-06896-3","DOI":"10.1186\/s12967-025-06896-3"},{"key":"12215_CR43","doi-asserted-by":"crossref","unstructured":"Alsalloum A, Shevchenko JA, Sennikov S (2024) NY-ESO\u20101 antigen: A promising frontier in cancer immunotherapy. Clin Translational Med, 14(9), e70020","DOI":"10.1002\/ctm2.70020"},{"key":"12215_CR44","doi-asserted-by":"crossref","unstructured":"Bose M (2023) PRAME Is a Multifaceted Cancer Testis Antigen with Diverse Roles. as a Biomarker and Therapeutic Target","DOI":"10.20944\/preprints202308.1028.v1"},{"issue":"1","key":"12215_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/PGP.0000000000000864","volume":"42","author":"JD Coppock","year":"2023","unstructured":"Coppock JD, Gradecki SE, Mills AM (2023) PRAME expression in endometrioid and serous endometrial carcinoma: a potential immunotherapeutic target and possible diagnostic pitfall. Int J Gynecol Pathol 42(1):35\u201342","journal-title":"Int J Gynecol Pathol"},{"key":"12215_CR46","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","volume":"9","author":"R Thomas","year":"2018","unstructured":"Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J (2018) NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol 9:947","journal-title":"Front Immunol"},{"issue":"15","key":"12215_CR47","doi-asserted-by":"publisher","first-page":"8125","DOI":"10.3390\/ijms23158125","volume":"23","author":"CH Lau","year":"2022","unstructured":"Lau CH, Seow KM, Chen KH (2022) Molecular mechanisms and clinical implications of PARP inhibitors in epithelial ovarian cancer. Int J Mol Sci 23(15):8125. https:\/\/doi.org\/10.3390\/ijms23158125","journal-title":"Int J Mol Sci"},{"key":"12215_CR48","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.68463","author":"D Dewani","year":"2024","unstructured":"Dewani D, Jaiswal A, Karwade P (2024) Poly (ADP-ribose) polymerase inhibitors in the treatment of advanced ovarian cancer. Cureus. https:\/\/doi.org\/10.7759\/cureus.68463","journal-title":"Cureus"},{"issue":"4","key":"12215_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.21037\/cco-20-69","volume":"9","author":"A Bahena-Gonz\u00e1lez","year":"2020","unstructured":"Bahena-Gonz\u00e1lez A, Toledo-Leyva A, Gallardo-Rinc\u00f3n D (2020) PARP inhibitors in ovarian cancer: Evidence for maintenance and treatment strategies. Chin Clin Oncol 9(4):51. https:\/\/doi.org\/10.21037\/cco-20-69","journal-title":"Chin Clin Oncol"},{"issue":"7","key":"12215_CR50","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.3390\/ijms22073765","volume":"22","author":"F Lopes-Coelho","year":"2021","unstructured":"Lopes-Coelho F, Martins F, Pereira SA, Serpa J (2021) Anti-angiogenic therapy: Current challenges and future perspectives. Int J Mol Sci 22(7):3765. https:\/\/doi.org\/10.3390\/ijms22073765","journal-title":"Int J Mol Sci"},{"key":"12215_CR51","doi-asserted-by":"publisher","first-page":"1491099","DOI":"10.3389\/fonc.2024.1491099","volume":"14","author":"J Xu","year":"2024","unstructured":"Xu J, Tang Z (2024) Angiogenic and antiangiogenic agents in the tumor microenvironment. Front Oncol 14:1491099. https:\/\/doi.org\/10.3389\/fonc.2024.1491099","journal-title":"Front Oncol"},{"issue":"24","key":"12215_CR52","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.3390\/cancers14246257","volume":"14","author":"A Skorda","year":"2022","unstructured":"Skorda A, Bay ML, Hautaniemi S, Lahtinen A, Kallunki T (2022) Kinase inhibitors in ovarian cancer. Cancers 14(24):6257. https:\/\/doi.org\/10.3390\/cancers14246257","journal-title":"Cancers"},{"issue":"9","key":"12215_CR53","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.3390\/biomedicines10092113","volume":"10","author":"A Rendell","year":"2022","unstructured":"Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M, Yu Y (2022) Targeting tyrosine kinases in ovarian cancer: Small molecule inhibitors and monoclonal antibodies\u2014Where are we now? Biomedicines 10(9):2113. https:\/\/doi.org\/10.3390\/biomedicines10092113","journal-title":"Biomedicines"},{"issue":"11","key":"12215_CR54","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.3390\/ijms21114154","volume":"21","author":"JM Metzler","year":"2020","unstructured":"Metzler JM, Burla L, Fink D, Imesch P (2020) Ibrutinib in gynaecological malignancies and breast cancer: A systematic review. Int J Mol Sci 21(11):4154. https:\/\/doi.org\/10.3390\/ijms21114154","journal-title":"Int J Mol Sci"},{"issue":"3","key":"12215_CR55","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3390\/cancers14030759","volume":"14","author":"S Mitra","year":"2022","unstructured":"Mitra S, Lami MS, Ghosh A, Das R, Tallei TE, Fatimawali, Islam F, Dhama K, Begum MY, Aldahish A, Chidambaram K, Emran TB (2022) Hormonal therapy for gynaecological cancers. Cancers 14(3):759","journal-title":"Cancers"},{"issue":"6","key":"12215_CR56","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3390\/cancers15061799","volume":"15","author":"VM Wagner","year":"2023","unstructured":"Wagner VM, Backes FJ (2023) Hormonal therapy for recurrent endometrial cancer. Cancers 15(6):1799. https:\/\/doi.org\/10.3390\/cancers15061799","journal-title":"Cancers"},{"issue":"1","key":"12215_CR57","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41392-020-0199-6","volume":"5","author":"Q Wang","year":"2020","unstructured":"Wang Q, Peng H, Qi X, Wu M, Zhao X (2020) Targeted therapies in gynaecological cancers. Signal Transduct Target Therapy 5(1):137. https:\/\/doi.org\/10.1038\/s41392-020-0199-6","journal-title":"Signal Transduct Target Therapy"},{"issue":"8","key":"12215_CR58","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1136\/ijgc-2023-005229","volume":"34","author":"R Trozzi","year":"2024","unstructured":"Trozzi R, Tuyaerts S, Annibali D, Pomares AH, Boog L, Van Dam P, Amant F (2024) An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent\/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study). Int J Gynecol Cancer 34(8):1217\u20131224","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"12215_CR59","doi-asserted-by":"publisher","first-page":"101978","DOI":"10.1016\/j.ijgc.2025.101978","volume":"35","author":"J He","year":"2025","unstructured":"He J, Chen M, Jia L, Wang Y (2025) Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets. Int J Gynecol Cancer 35(9):101978","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"12215_CR60","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/GCO.0000000000000838","volume":"35","author":"J Tymon-Rosario","year":"2023","unstructured":"Tymon-Rosario J, Gorman M, Richardson DL, Washington C, Santin AD (2023) Advances in antibody-drug conjugates for gynecologic malignancies. Curr Opin Obstet Gynecol 35(1):6\u201314","journal-title":"Curr Opin Obstet Gynecol"},{"key":"12215_CR61","doi-asserted-by":"publisher","unstructured":"Moore KN, Liu JF, Lorusso DL (2025) State of the art: Therapies now and around the corner for gynaecologic cancers. ASCO Educational Book 45(3). https:\/\/doi.org\/10.1200\/edbk-25-473114","DOI":"10.1200\/edbk-25-473114"},{"issue":"4","key":"12215_CR62","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3390\/cancers16040770","volume":"16","author":"EM Wilson","year":"2024","unstructured":"Wilson EM, Eskander RN, Binder PS (2024) Recent therapeutic advances in gynaecologic oncology. Cancers 16(4):770. https:\/\/doi.org\/10.3390\/cancers16040770","journal-title":"Cancers"},{"issue":"2","key":"12215_CR63","doi-asserted-by":"publisher","first-page":"149","DOI":"10.37349\/etat.2022.00077","volume":"3","author":"M Nerone","year":"2022","unstructured":"Nerone M, Del Grande M, Sessa C, Colombo I (2022) Advancing antibody-drug conjugates in gynecological malignancies: myth or reality? Explor Target Anti-tumor Therapy 3(2):149","journal-title":"Explor Target Anti-tumor Therapy"},{"issue":"2","key":"12215_CR64","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.pathol.2023.10.013","volume":"56","author":"RW Wong","year":"2024","unstructured":"Wong RW, Cheung ANY (2024) Predictive and prognostic biomarkers in female genital tract tumours. Pathology 56(2):214\u2013227. https:\/\/doi.org\/10.1016\/j.pathol.2023.10.013","journal-title":"Pathology"},{"issue":"4","key":"12215_CR65","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3892\/ol.2023.14012","volume":"26","author":"T Minaguchi","year":"2023","unstructured":"Minaguchi T, Shikama A, Akiyama A, Satoh T (2023) Molecular biomarkers for facilitating genome-directed precision medicine in gynaecological cancer (Review). Oncol Lett 26(4):426. https:\/\/doi.org\/10.3892\/ol.2023.14012","journal-title":"Oncol Lett"},{"issue":"1","key":"12215_CR66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/jpm12010003","volume":"12","author":"N Bizzarri","year":"2021","unstructured":"Bizzarri N, Nero C, Sillano F, Ciccarone F, D\u2019Oria M, Cesario A, Fragomeni SM, Testa AC, Fanfani F, Ferrandina G, Lorusso D, Fagotti A, Scambia G (2021) Building a personalized medicine infrastructure for gynaecological oncology patients in a high-volume hospital. J Personalized Med 12(1):3. https:\/\/doi.org\/10.3390\/jpm12010003","journal-title":"J Personalized Med"},{"key":"12215_CR67","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2024.111","author":"AL Ponton-Almodovar","year":"2024","unstructured":"Ponton-Almodovar AL, Sanderson SC, Rattan R, Bernard JJ, Horibata S (2024) Ovarian tumor microenvironment contributes to tumor progression and chemoresistance. Cancer Drug Resist. https:\/\/doi.org\/10.20517\/cdr.2024.111","journal-title":"Cancer Drug Resist"},{"issue":"19","key":"12215_CR68","doi-asserted-by":"publisher","first-page":"10443","DOI":"10.3390\/ijms251910443","volume":"25","author":"VP Snijesh","year":"2024","unstructured":"Snijesh VP, Krishnamurthy S, Bhardwaj V, Punya KM, A. S. NM, Almutadares M, Albaqami WF (2024) SHH signaling as a key player in endometrial cancer: unveiling the correlation with good prognosis, low proliferation, and anti-tumor immune milieu. Int J Mol Sci 25(19):10443","journal-title":"Int J Mol Sci"},{"key":"12215_CR69","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.critrevonc.2015.08.004","volume":"97","author":"K Asi\u0107","year":"2016","unstructured":"Asi\u0107 K (2016) Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies. Crit Rev Oncol\/Hematol 97:178\u2013196. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.08.004","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"12215_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-824299-5.00008-3","author":"N Sabnis","year":"2021","unstructured":"Sabnis N, Mathew E, Dossou AS, Zheng A, Nagarajan B, Fudala R, Lacko AG (2021) Mechanisms of chemoresistance and approaches to overcome its impact in gynaecologic cancers. Acad Press. https:\/\/doi.org\/10.1016\/B978-0-12-824299-5.00008-3","journal-title":"Acad Press"},{"key":"12215_CR71","doi-asserted-by":"publisher","unstructured":"Sarvepalli D, Rashid MU, Zafar H, Jehanzeb S, Zahid E, Ahmad S (2021) Ovarian cancer: Targeted therapies and mechanisms of resistance. Academic Press. https:\/\/doi.org\/10.1016\/B978-0-12-824299-5.00014-9","DOI":"10.1016\/B978-0-12-824299-5.00014-9"},{"issue":"18 Suppl","key":"12215_CR72","doi-asserted-by":"publisher","first-page":"A003","DOI":"10.1158\/1538-7445.ovarian25-a003","volume":"85","author":"S Bystrup","year":"2025","unstructured":"Bystrup S, Imbach KJ, Garcia S, Bernabeu AF, Grases D, Porta-Pardo E, Barretina J, Valdivieso L, Sent\u00eds PG, Peguera AB (2025) Mapping the tumor microenvironment: Spatial transcriptomic insights into ovarian cancer progression and resistance (Abstract). Cancer Res 85(18 Suppl):A003. https:\/\/doi.org\/10.1158\/1538-7445.ovarian25-a003","journal-title":"Cancer Res"},{"key":"12215_CR73","doi-asserted-by":"publisher","first-page":"1586315","DOI":"10.3389\/fimmu.2025.1586315","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Liu N, Guo X, Han R, Bai J, Zhong J, Wang Q (2025) Immune microenvironment in endometrial carcinoma. Front Immunol 16:1586315. https:\/\/doi.org\/10.3389\/fimmu.2025.1586315","journal-title":"Front Immunol"},{"key":"12215_CR74","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ygyno.2025.01.006","volume":"193","author":"A Clements","year":"2025","unstructured":"Clements A, Enserro D, Strickland KC, Previs R, Matei D, Mutch D, Powell M, Klopp A, Miller DS, Jr Small W, DiSilvestro P, Spirtos N, Cosgrove C, Sfakianos G, Liu JR, Vargas R, Shahin M, Corr B, Dessources K, Ueland F, Secord AA (2025) Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258. Gynaecologic Oncol 193:119\u2013129. https:\/\/doi.org\/10.1016\/j.ygyno.2025.01.006","journal-title":"Gynaecologic Oncol"},{"key":"12215_CR75","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2025-0157-CP","author":"G Turashvili","year":"2025","unstructured":"Turashvili G, Karnezis AN, Hulkower KI, Hebert C, Harik L, Crothers B, Giannico G, Deeb KK, Hanley K, Ganesan R, Mills A, Buza N (2025) Reporting biomarker testing results in gynaecologic carcinoma. Arch Pathol Lab Med. https:\/\/doi.org\/10.5858\/arpa.2025-0157-CP","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"12215_CR76","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5858\/arpa.2014-0063-ED","volume":"139","author":"JD Khoury","year":"2015","unstructured":"Khoury JD, Catenacci DVT (2015) Next-generation companion diagnostics: Promises, challenges, and solutions. Arch Pathol Lab Med 139(1):11\u201313. https:\/\/doi.org\/10.5858\/arpa.2014-0063-ED","journal-title":"Arch Pathol Lab Med"},{"key":"12215_CR77","doi-asserted-by":"publisher","unstructured":"Welcher R (2019) Use of companion diagnostics in precision medicine. In: Badve S, Kumar G (eds) Predictive biomarkers in oncology. Springer. https:\/\/doi.org\/10.1007\/978-3-319-95228-4_49","DOI":"10.1007\/978-3-319-95228-4_49"},{"issue":"1","key":"12215_CR78","doi-asserted-by":"publisher","first-page":"e35596","DOI":"10.1002\/cncr.35596","volume":"131","author":"EM Wilson","year":"2025","unstructured":"Wilson EM, Huang R, Jones KD, Hagemann IS, Temkin SM, McAlpine JN, Powell MA, Kepper MM, Hagemann AR (2025) Challenges in molecular classification in early-stage endometrial cancer. Cancer 131(1):e35596. https:\/\/doi.org\/10.1002\/cncr.35596","journal-title":"Cancer"},{"issue":"3","key":"12215_CR79","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3978\/j.issn.2218-676X.2015.06.04","volume":"4","author":"N Goossens","year":"2015","unstructured":"Goossens N, Nakagawa S, Sun X, Hoshida Y (2015) Cancer biomarker discovery and validation. Translational Cancer Res 4(3):256\u2013269. https:\/\/doi.org\/10.3978\/j.issn.2218-676X.2015.06.04","journal-title":"Translational Cancer Res"},{"key":"12215_CR80","doi-asserted-by":"publisher","unstructured":"Kamal M (2015) Challenges for the clinical implementation of precision medicine trials. In C. Le Tourneau & M. Kamal (Eds.), Pan-cancer integrative molecular portrait towards a new paradigm in precision medicine (pp. 139\u2013149). Springer. https:\/\/doi.org\/10.1007\/978-3-319-22189-2_9","DOI":"10.1007\/978-3-319-22189-2_9"},{"issue":"12","key":"12215_CR81","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11864-018-0584-3","volume":"19","author":"C Fan","year":"2018","unstructured":"Fan C, Reader J, Roque DM (2018) Review of immune therapies targeting ovarian cancer. Curr Treat Options Oncol 19(12):74","journal-title":"Curr Treat Options Oncol"},{"key":"12215_CR82","doi-asserted-by":"publisher","first-page":"104063","DOI":"10.1016\/j.critrevonc.2023.104063","volume":"188","author":"M Tu","year":"2023","unstructured":"Tu M, Xu J (2023) Advances in immunotherapy for gynecological malignancies. Crit Rev Oncol\/Hematol 188:104063","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"141","key":"12215_CR83","first-page":"39","volume":"26","author":"G Menderes","year":"2018","unstructured":"Menderes G, Lopez S, Han C, Altwerger G, Gysler S, Varughese J, Schwartz PE, Santin AD (2018) Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma. Discov Med 26(141):39\u201350","journal-title":"Discov Med"},{"issue":"12","key":"12215_CR84","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11912-018-0740-8","volume":"20","author":"YL Liu","year":"2018","unstructured":"Liu YL, Zamarin D (2018) Combination immune checkpoint blockade strategies in gynaecological cancers. Curr Oncol Rep 20(12):94. https:\/\/doi.org\/10.1007\/s11912-018-0740-8","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"12215_CR85","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.3390\/cancers14051352","volume":"14","author":"VK Maruthi","year":"2022","unstructured":"Maruthi VK, Khazaeli M, Jeyachandran D, Desouki MM (2022) The clinical utility and impact of next-generation sequencing in gynaecologic cancers. Cancers 14(5):1352. https:\/\/doi.org\/10.3390\/cancers14051352","journal-title":"Cancers"},{"issue":"2","key":"12215_CR86","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3390\/jcm9020585","volume":"9","author":"C Casas-Arozamena","year":"2020","unstructured":"Casas-Arozamena C, Diaz EC, Moiola CP, Alonso-Alconada L, Ferreir\u00f3s A, Abalo A, L\u00f3pez Gil C, Oltra SS, De Santiago J, Cabrera S, Sampayo V, Bouso M, Arias E, Cueva J, Colas E, Vilar A, Gil-Moreno A, Abal M, Moreno-Bueno G, Muinelo-Romay L (2020) Genomic profiling of uterine aspirates and cfDNA as an integrative liquid biopsy strategy in endometrial cancer. J Clin Med 9(2):585. https:\/\/doi.org\/10.3390\/jcm9020585","journal-title":"J Clin Med"},{"issue":"1","key":"12215_CR87","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/gco.0000000000000335","volume":"29","author":"EN Prendergast","year":"2017","unstructured":"Prendergast EN, Elvin JA (2017) Genomic profiling of gynaecologic cancers and implications for clinical practice. Curr Opin Obst Gynecol 29(1):18\u201325. https:\/\/doi.org\/10.1097\/gco.0000000000000335","journal-title":"Curr Opin Obst Gynecol"},{"issue":"7","key":"12215_CR88","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11912-021-01073-3","volume":"23","author":"C Cosgrove","year":"2021","unstructured":"Cosgrove C, Barrington DA, Backes FJ (2021) Impact of molecular classification on treatment paradigms in uterine cancers. Curr Oncol Rep 23(7):75. https:\/\/doi.org\/10.1007\/s11912-021-01073-3","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"12215_CR89","doi-asserted-by":"publisher","first-page":"188","DOI":"10.31083\/j.ceog4908188","volume":"49","author":"S Saharti","year":"2022","unstructured":"Saharti S (2022) Molecular signature of gynaecological malignancies: A narrative review. Clin Exp Obstet Gynecol 49(8):188. https:\/\/doi.org\/10.31083\/j.ceog4908188","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"9","key":"12215_CR90","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1017\/S0007114524000308","volume":"131","author":"R Francisco","year":"2024","unstructured":"Francisco R, Jesus F, Nunes CL, Santos P, Alvim M, Campa F, Schoeller DA, Lukaski H, Mendonca GV, Sardinha LFCB, Silva AMLA (2024) H2OAthletes study protocol: effects of hydration changes on neuromuscular function in athletes. Br J Nutr 131(9):1579\u20131590. https:\/\/doi.org\/10.1017\/S0007114524000308","journal-title":"Br J Nutr"},{"issue":"9","key":"12215_CR91","doi-asserted-by":"publisher","first-page":"101978","DOI":"10.1016\/j.ijgc.2025.101978","volume":"35","author":"J He","year":"2025","unstructured":"He J, Chen M, Li J, Wang Y (2025) Antibody\u2013drug conjugates in gynaecologic cancer: Current landscape, clinical data, and emerging targets. Int J Gynaecol Cancer 35(9):101978. https:\/\/doi.org\/10.1016\/j.ijgc.2025.101978","journal-title":"Int J Gynaecol Cancer"},{"issue":"2","key":"12215_CR92","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jjco\/hyaa214","volume":"51","author":"H Nishio","year":"2021","unstructured":"Nishio H, Iwata T, Aoki D (2021) Current status of cancer immunotherapy for gynaecologic malignancies. Jpn J Clin Oncol 51(2):167\u2013172. https:\/\/doi.org\/10.1093\/jjco\/hyaa214","journal-title":"Jpn J Clin Oncol"},{"key":"12215_CR93","doi-asserted-by":"crossref","unstructured":"Horgan, D., Tanner, M., Aggarwal, C., Thomas, D., Grover, S., Basel-Salmon, L., \u2026Subbiah, V. (2025). Precision oncology: a global perspective on implementation and policy development. JCO Global Oncology, 11, e2400416","DOI":"10.1200\/GO-24-00416"},{"key":"12215_CR94","doi-asserted-by":"crossref","unstructured":"Masucci M (2025) Implementing Precision Cancer Medicine: organisational challenges, innovations, and the role of Molecular Tumour Boards (Doctoral dissertation, Karolinska Institutet)","DOI":"10.69622\/28938518.v1"},{"key":"12215_CR95","doi-asserted-by":"crossref","unstructured":"Graf, T., Boos, L. A., Mehra, T., Miglino, N., Sobottka, B., R\u00fcschoff, J. H., \u2026 Wicki,A. (2025). Precision Oncology Guided by Genomic Profiling in Breast Cancer: Real-World Data from a Molecular Tumor Board. Cancers, 17(15), 2435","DOI":"10.3390\/cancers17152435"},{"key":"12215_CR96","doi-asserted-by":"crossref","unstructured":"Ma J, Bhardwaj V, Lobie PE, Pandey V (2026) Metabolic plasticity in pancreatic ductal adenocarcinoma progression and response to treatment. Molecular Cancer","DOI":"10.1186\/s12943-026-02620-x"},{"key":"12215_CR97","doi-asserted-by":"publisher","first-page":"852746","DOI":"10.3389\/fonc.2022.852746","volume":"12","author":"V Bhardwaj","year":"2022","unstructured":"Bhardwaj V, Sharma A, Parambath SV, Gul I, Zhang X, Lobie PE, Pandey V (2022) Machine learning for endometrial cancer prediction and prognostication. Front Oncol 12:852746","journal-title":"Front Oncol"},{"issue":"7","key":"12215_CR98","doi-asserted-by":"publisher","first-page":"e70243","DOI":"10.1002\/mco2.70243","volume":"6","author":"T Wolde","year":"2025","unstructured":"Wolde T, Bhardwaj V, Pandey V (2025) Current bioinformatics tools in precision oncology. MedComm 6(7):e70243","journal-title":"MedComm"},{"key":"12215_CR99","doi-asserted-by":"publisher","first-page":"123113","DOI":"10.1016\/j.lfs.2024.123113","volume":"357","author":"P Huang","year":"2024","unstructured":"Huang P, Wolde T, Bhardwaj V, Zhang X, Pandey V (2024) TFF3 and PVRL2 co-targeting identified by multi-omics approach as an effective cancer immunosuppression strategy. Life Sci 357:123113","journal-title":"Life Sci"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12215-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12215-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12215-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:21:04Z","timestamp":1782858064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12215-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12215"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12215-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All abbreviations are defined at their first occurrence in the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Abbreviations"}},{"value":"During the preparation of this review, the authors used ChatGPT to improve the language and clarity of the manuscript and to assist in the generation of schematic illustrations. Following the use of this tool, all text and figures were carefully reviewed, edited, and validated by the authors to ensure scientific accuracy and relevance. The authors take full responsibility for the integrity, originality, and content of the publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies in the writing process"}}],"article-number":"1038"}}